StageZero Life Sciences Ltd T.SZLS

Alternate Symbol(s): SZLSF

Healthcare Biotechnology

StageZero Life Sciences, Ltd. is a Canada-based vertically integrated healthcare company. The Company is engaged in improving the early detection and management of cancer and other chronic diseases through diagnostics and telehealth programs that provide clinical interventions to assist patients who have cancer (COC Protocol), and help patients reduce the risk of developing late-stage disease (AVRT). Its test, Aristotle, is the first mRNA multi-cancer panel for simultaneously screening for multiple cancers from a single sample of blood with high sensitivity and specificity for each cancer. Aristotle uses mRNA technology to identify the molecular signatures of multiple cancer types and is built on the Company's patented technology platform, the Sentinel Principle. The Care Oncology Clinic offers a supervised treatment regimen (the COC Protocol) for people diagnosed with cancer of any type or stage. Its ColonSentry is a proprietary blood test for screening for Colorectal Cancer.

TSX:SZLS - Post by User

StageZero Life Sciences Ltd > So much good news...

<< Previous

Bullboard Posts

Next >>

Comment by gojotv!on May 27, 2021 11:19am

63 Views

Post# 33275559

RE:So much good news...

When I look at all the reasons StageZero stands to double in price (in accordance with analysts' targets) it makes me laugh that some investors are so allergic to making money! lol
GLTA!

gojotv! wrote: Since April 1st:

StageZero launches Aristotle, the world's only highly accurate, non-invasive multi-cancer screening blood test amid a worldwide backlog in cancer tests due to the Covid crisis.

SZLS announces a LOI to acquire "Health Clinics Limited" which includes "Care Oncology" telehealth services, a first foray into the growing multi-million dollar telehealth market.

"Care Oncology" is given first priority to introduce Aristotle to its thousands of patients in the U.S. and U.K.

Initial Aristotle deployment is confirmed in interview with SZLS CEO. Revenues will appear on the books for Q2.

SZLS actively seeks more partnerships and affirms it is still offering its covid and cancer screening to employers. Some such projects appear to be underway.

Covid testing revenues for Q1 remain relatively stable despite international travel shutdown in early 2021.

Most accurate home PCR saliva tests for Covid now made more convenient and accessible to end users through Ichor distribution online and in Rexall pharmacies.

Rexall in-house clinics and telehealth services a potential fit for SZLS long-term strategy.

Europe announces imminent re-opening of its borders to international vaccinated travellers pending a negative PCR test, further expanding SZLS's revenue potential.

Market movers express enthusiastic interest in StageZero in several online interviews and presentations.

Price targets by Drolet and Clarus - $1.08 and $1.25 respectively.

Share price currently near or at "oversold" following April "short attack" and apparent manipulation. A bargain.

Not bad for just about six weeks' work, eh?
Good luck to all longs!